G lobally, cardiovascular disease is a leading cause of morbidity and mortality and most commonly presents as coronary artery disease, which is characterized by reduced blood flow to the myocardium. 1 This restriction can lead to ischemic damage and the loss of cardiomyocytes. Current methods of treatment for coronary artery disease primarily aim to reestablish blood flow and reduce the workload of the heart through pharmacological means. However, research
indicates that angiogenesis has the potential for improving long-term treatment of damage caused by myocardial infarction (MI). Various pathways and molecules are involved in the initiation and regulation of angiogenesis, including vascular endothelial growth factor (VEGF), a major architect of this process. VEGF is a potent mitogen specific to endothelial cells and a secreted dimeric protein that is involved in the induction of angiogenesis. 2, 3 VEGF follows a tyrosine kinase receptor pathway to promote endothelial cell differentiation and migration. 3 In a previous study, we examined the effect of adenoviral administration of VEGF along with angiopoietin-1 in diabetic mice after the induction of MI. 4 We observed markedly enhanced neovascularization and diminished cardiac fibrosis in the treatment group. We also noted an improved cardiac functions as assessed by echocardiography. However, our interest shifted from VEGF to the molecules downstream of VEGF that may be involved in angiogenesis after clinical trials of VEGF failed to yield similar outcomes in patients with cardiovascular disease. [5] [6] [7] In addition to VEGF, several additional proteins have been identified as having proangiogenic characteristics. Nuclear factor j-light-chain enhancer of activated B cells (NFjB) is a transcription factor that controls DNA transcription and is involved in cytokine production and cell survival. 8 Phosphorylation of mitogen-activated protein kinase-activated kinase 2 (MK2) has been shown to aid in the activation of NFjB, which, as described above, aids in angiogenesis. 8 Another molecule, the gap junction protein connexin 43 (Cx43), has been implicated in cardioprotection. 9 Inhibiting Cx43 reduces the expression of VEGF in human endothelial progenitor cells by stunting the angiogenic process. 10 Tyrosine kinase receptor Flk-1, also known as VEGF receptor-2, (VEGFR2), is a major receptor of VEGF. Recently, we have shown increased ischemic skin flap survivability and reduced necrosis by Pellino-1 (Peli1) gene therapy in heterozygous Flk-1 (Flk-1 +/À )-knockout mice. 11 In an earlier study, 12 we found diminished heart function with the same heterozygous Flk-1/VEGFR2 (Flk-1 +/À )-knockout mice, even in the presence of ischemic preconditioning (PC). However, the mediating role of VEGF/Flk-1 downstream signaling in the ischemic myocardium during neovascularization remains unclear. Therefore, in the present study we explored the downstream molecular mechanism of VEGF signaling in genetically engineered Flk-1 +/À mice subjected to MI and subsequent rescue by the newly identified proangiogenic molecule, Peli1. Peli1 is 1 of 3 main Pellino molecules from the E3 ubiquitin ligase family. In the immune system, Peli1 is necessary for interleukin 1-mediated activation of NFjB. Peli1 additionally plays a role in Toll-like receptor signaling and negative regulation of T cells. 13 Although the immunological effects of Peli1 have been extensively studied, the involvement of Peli1 in angiogenesis has not yet been examined. Peli1 upregulates MK2 through ubiquitination and activation of inhibitor of apoptosis-2 (IAP2), which in turn facilitates the ubiquitination and degradation of tumor necrosis factor receptor-associated factor-3, a negative regulator of MK2. 14 Peli1 also plays a role in the activation of NFjB. 13 Peli1 mediates activation of IjB kinase (IKK) via the Toll/Interleukin-1 receptor homology-domain-containing adaptor-inducing interferon-b-dependent Toll-like receptor pathway. 15 Interestingly, the phosphoinositide 3-kinase/ protein kinase B (PI3K/Akt) pathway functions through IKK in a fashion that promotes the phosphorylation of NFjB. 16, 17 Increased phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) promote angiogenesis, likely via IKK in a manner involving NFjB and b-catenin activation. 18 The present study demonstrates the indispensable role of Peli1 in angiogenic remodeling and cardiac repair using loss of function related to an Flk-1 +/À mouse model of MI. We found that a reduction of Flk-1 correlates with decreased expression of Peli1. Therefore, it is possible that Peli1 plays a role in angiogenesis and cardiac repair downstream of VEGF/Flk-1. Given previous knowledge regarding the benefits of triggering the VEGF cascade, the importance of Flk-1, and the finding that the knockdown of Flk-1 downregulates Peli1, we hypothesize that overexpression of Peli1 may protect the heart from ischemic damage after MI, providing a novel target for therapeutic development.
Clinical Perspective
What Is New?
• Disruption of vascular endothelial growth factor signaling by inhibition of Flk-1 inhibits Pellino-1 expression and reduces angiogenic effect and cardiac repair.
• Compared with normal healthy heart, Pellino-1 expression was found to be downregulated in the infarcted myocardium.
• Overexpression of Pellino-1 initiates an angiogenic effect and amelioration of cardiac remodeling following myocardial infarction.
• Deterioration of cardiac repair and increased ventricular remodeling in Flk-1-knockout mice subjected to myocardial infarction was rectified with Pellino-1 treatment.
What Are the Clinical Implications?
• Our work expanded the understanding of a novel molecular mechanism of vascular endothelial growth factor-mediated signaling via a newly identified therapeutic molecule, Pellino-1, in the ischemic myocardium for cardiac repair.
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Materials and Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because other related projects are in progress.
In Vitro Experiments
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (Walkersville, MD). Cells were maintained in endothelial cell growth medium 2 with supplemental growth factors and antibiotics, per the manufacturer's specifications.
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Angiogenic Tube Formation Assay Tube formation was assessed after 8 hours of seeding using an Olympus QColor 3TM digital camera mounted on an Olympus BH2 microscope. Each well was photographed at 9200 magnification.
Cell Proliferation
The HUVECs underwent siRNA (C.siRNA or Peli1.siRNA) transfection for 48 hours, followed by 8 hours of hypoxia and 24 hours of reoxygenation. Five thousand cells per well were subsequently seeded onto a 96-well plate and followed for 0, 24, and 48 hours. A CyQUANT cell proliferation assay was performed as per the manufacturer's instructions (Cat# C7026, Molecular Probes, Thermo Fisher Scientific, Waltham, MA).
Wound Assay
HUVECs that underwent siRNA transfection for 48 hours (C.siRNA or Peli1.siRNA) in 12-well plates, followed by 8 hours of hypoxia and 24 hours of reoxygenation, were allowed to reach 90% confluence. Uniform wounds were created with a sterile 200-lL pipette tip in the HUVECs monolayer and supplemented with fresh EBM-2 medium with reduced serum (n=3-4/group). Wounds were imaged at 0, 3, 6, 12, 24, and 36 hours using the 94 objective of an inverted microscope (iRis Digital Cell Imaging System, Logos Biosystems, Annandale, VA). The wound area was calculated from each image using ImageJ software (NIH, Bethesda, MD), and wound closure (%) was calculated using a previously reported formula. 11, 19, 20 In Vivo Experiments 
Mouse Model of MI and Gene Therapy
Mice from 8 to 12 weeks of age were used in this study. All mice were anesthetized, intubated, and positioned for surgery. Anesthesia was accomplished through intraperitoneal administration of ketamine hydrochloride (100 mg/kg) and xylazine (10 mg/kg). We also administered the antibiotic cefazolin (25 mg/kg) prophylactically. After anesthesia, the mice were intubated and ventilation was initiated (150 strokes/min, stroke volume of 300 lL) using a rodent ventilator (model 845; Harvard Apparatus, Holliston, MA). The mice were then placed in a right decubitus position to expose the left side of the chest wall for left lateral thoracotomy. The fur was removed from the left chest wall area using commercial hair removal cream (Nair â lotion with cocoa butter and vitamin E), and the incision area was cleaned with a 70% isopropyl alcohol prep pad followed by betadine application. During the operative phase, an incision was made at the fourth intercostal region, and a left lateral thoracotomy was performed. The muscles and fascia were separated using a blunt dissection and portable electrocautery (HIT1 Change-ATip TM ; Bovie Medical Corp, Clearwater, FL) to enter the left thoracic cavity and expose the heart. The left anterior descending coronary artery (LAD) was visualized, and an 8-0 prolene suture with a tapered needle was used for ligation. To induce permanent MI, the needle and suture were passed under the LAD just below the edge of the left atrium and ligated. Visual evidence of pale color distal to the occlusion point, indicating decreased blood flow, was used to ensure that the occlusion was successful. In sham-treated animals,
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Thirunavukkarasu et al the needle and suture were passed under the LAD and removed without ligation of the artery. The thoracotomy and skin were then closed in normal operative fashion. For the gene therapy experiments, we administered the adenoviral vectors (Ad) carrying LacZ or Peli1 immediately after the MI or sham surgical procedure. Mice in the Ad-Peli1 treatment groups were administered an adenoviral vector encoding Peli1 (1910 9 pfu), and those in the Ad-LacZ treatment (1910 9 pfu) groups were administered an adenoviral vector encoding LacZ. Mice in each treatment group were injected with adenovirus (in 50 lL of PBS) at 4 locations in the peri-infarct region known as the "high-risk area" using a 30-gauge needle (12.5 lL injected at each location). The apex of the left ventricle (LV) was excluded as a site of administration because this area bears a higher risk of the needle entering the ventricle and releasing adenovirus into general circulation. After administration of the adenovirus, the incision was closed.
The surgical area was cleaned with Betadine after the skin was closed to prevent infection. Buprenorphine (0.05-0.1 mg/kg) was also postoperatively and subcutaneously administered for pain management. The mice were weaned off the ventilator and placed on a heating pad to recover from anesthesia. The mice were subsequently placed on a painmanagement schedule that included receiving buprenorphine (0.05-0.1 mg/kg) every 12 hours for 3 days. 21 We modified the previously described method to conduct preconditioning (PC) in mice (PC limits infarct size following regional ischemia-reperfusion in in situ mouse hearts). Briefly, the LAD was identified after intubation and thoracotomy, and an 8-0 prolene suture was passed underneath. A small piece of tubing was placed on the myocardial surface, and the suture was tied around the tubing. After 4 minutes, the tied knots were released. We repeated this process for 4 cycles; each cycle comprised 4 minutes each of ischemia and reperfusion. After the fourth cycle of reperfusion, the LAD was permanently ligated, the chest was closed, and the animal was allowed to recover before extubation. 22 
Experimental Groups and Treatments
For experiments involving Flk-1 +/À mice, the animals were divided into 4 groups: (1) 
Immunohistochemistry for Capillary and Arteriolar Densities and the Expression of Cx43
To measure capillary and arteriolar densities, heart tissues collected after surgery were fixed overnight in 10% buffered formalin (Sigma-Aldrich, St. Louis, MO) followed by 70% ethanol and embedded in paraffin blocks. ) were made in the area at risk after superimposing a calibrated morphometric grid on each image using Adobe Photoshop CS4 software (Adobe Systems, San Jose, CA).
To estimate arteriolar density, tissue sections were counterstained with mouse anti-a-smooth muscle actin (1:100 in PBS; Cat# ab7817, Abcam Inc, Cambridge, MA). The tissue sections were then incubated with donkey antimouse secondary antibody labeled with Alexa Fluor 488 (1:200 in PBS; Invitrogen, Carlsbad, CA) for 1 hour at room temperature. The sections were mounted with a coverslip using Vectashield fluorescent mounting medium (Vector Laboratories Inc, Burlingame, CA). Tissue images were taken using an Olympus BX53 microscope with an Olympus DP73 digital color camera attached to it. Images were acquired and diameter was measured using CellSens Dimension (version 1.6) software. The arteriolar density observed in each image was expressed as the count per 1 mm 2 .
Immunohistochemistry for Cx43 expression was performed only for mice in the Ad-LacZMI and Ad-Peli1MI groups. Mice were euthanized 4 days after the induction of MI and gene therapy. The hearts were removed, and tissue sections were embedded in paraffin blocks as described above. The sections were stained using anti-rabbit Cx43 (1:100 in PBS; Cat# C6219, Sigma-Aldrich, St. Louis, MO) and anti-mouse cTnT 
Immunohistochemistry to Measure the Transfection Efficiency of Ad-LacZ and Ad-Peli1
To ensure that our gene-transfer technique was effective in vivo, adenovirus gene expression was evaluated in the sham-operated control groups 4 days after treatment. Hearts were exposed by left lateral thoracotomy using the method described above and injected with either Ad-Peli1 or Ad-LacZ at 4 sites. Four days later, the mice were euthanized, and the hearts were removed and fixed overnight in 10% formaldehyde, followed by paraffin embedding. Sections 5 lm thick were deparaffinized using 29 washes of HistoClear (National Diagnostics, Atlanta, GA). They were then rehydrated in an alcohol gradient in the order of 29 100%, 90%, 80%, and 70%, for 5 minutes each. The sections were washed 3 times in PBS and then in antigen retrieval buffer (Cat# S1699, Dako, Santa Clara, CA). Next, endogenous peroxidase was blocked using 0.3% hydrogen peroxide in PBS for 30 minutes. By use of a buffered casein solution (Power Block TM universal blocking reagent; Cat# HK085-5K, Bio Genex, San Ramon, CA), nonspecific binding sites were then blocked at room temperature for 8 minutes. The slides were washed again 3 times in PBS and then stained for Peli1 using anti-Pellino-1 antibody (1:100 dilution in PBS; Cat# SC-31619, Santa Cruz Biotechnology Inc, Dallas, TX) overnight at 4°C followed by incubation with anti-goat secondary antibody labeled with Alexa Fluor 488 (1:200 dilution; Cat# A11055; Invitrogen, Carlsbad, CA) for 1 hour. Nuclei were counterstained with TO-PRO-3 Iodide. Slides were washed and mounted with Fluoromount TM and visualized using a Zeiss LSM 510 Meta confocal microscope.
Western Blot Analysis of Peli1, p-Flk-1, p-MK2, p-eNOS, p-Akt, p-IjBa and b catenin
The peri-infarct region of the LV was collected either 24 hours or 4 days after surgery, flash-frozen in liquid nitrogen, and stored at À80°C for Western blot analysis. To quantitatively analyze the expressions of various proteins, we used the SDS-PAGE Western blot technique. Tissue samples were homogenized using CelLytic TM NuCLEAR TM Extraction Kit (SigmaAldrich, St. Louis, MO). The cytosolic and nuclear protein was separated, and the protein concentration was established using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Ten-percent polyacrylamide gels were used for electrophoresis for Peli1, p-MK2/MK2, p-AKT/AKT and p-IjBa/ IjBa, and 7.5% gels were used for p-Flk-1/Flk-1, p-eNOS/ eNOS and b-catenin (cytosolic). b-catenin from nuclear protein fraction was separated using 4-15% gels. GAPDH, b-actin, Vinculin or Histone-H3 was used as a loading control. In addition, each protein's dephosphorylated form was used as a second loading control for each protein. The p-Flk-1 (1:1000 dilution; Cat# ab194806), Flk-1 (1:1000 dilution; Cat# ab39256), p-MK2 (1:500 dilution; Cat# 3041), MK2 (1:500 dilution, Cat# 3042), p-eNOS (1:1000 dilution; Cat# 9571), eNOS (1:1000 dilution; Cat# 9572), p-Akt (1:1000 dilution; Cat# 9271), and Akt (1:1000 dilution; Cat# 9272) antibodies were purchased from Cell Signaling Technology (Danvers, MA). p-IjBa (1:1000 dilution; Cat# ab47752), antivinculin (1:1000; Cat# ab18058) was purchased from Abcam Inc (Cambridge, MA), and the IjBa (1:1000 dilution; Cat# SC-847), b-catenin (1:1000 dilution; Cat# SC-7963) and Histone H3 (1:1000 dilution; Cat# SC-10809) antibody was purchased from Santa Cruz Biotechnology, Inc (Dallas, TX). The GAPDH antibody (1:4000 dilution, Cat# AM4300) and anti-b-actin (1:2000 dilution, Cat# A5441) was purchased from Thermo Fisher Scientific (Waltham, MA) and Sigma-Aldrich, St. Louis,
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Histochemical Staining to Determine the Extent of Myocardial Fibrosis
To measure the extent of myocardial fibrosis, paraffinembedded sections of the heart were stained using PicroSirius Red (Cat# 365548, Sigma-Aldrich, St. Louis, MO). The paraffinembedded sections were then deparaffinized using Histo-Clear (National Diagnostics, Atlanta, GA) and rehydrated using an alcohol gradient (29 100%, followed by 90%, 80%, and 70%). The sections were washed in distilled water and stained with PicroSirius Red for 1 hour before being washed twice in acidified water for 3 minutes each. The slides were then placed twice in 100% alcohol and Histo-Clear and mounted using Permount mounting medium (Thermo Fisher Scientific, Waltham, MA). Tissue images were taken at 9400 magnification using an Olympus BH2 microscope. ImageJ software (NIH, Bethesda, MD) was used to measure the degree of fibrosis.
Echocardiography
Thirty days after the induction of MI, the mice were sedated using isoflurane (3% inhaled). The mice were secured with tape to a custom mold in a supine position to maintain a natural body shape, and the fur was removed from the chest wall using commercial hair removal cream (Nair â lotion with cocoa butter and vitamin E). Ultrasound gel was spread over the chest, and an ultrasound biomicroscopy (Vevo 770, Visual-Sonics Inc, Toronto, ON, Canada) with a 25-MHz transducer was used for imaging. Left ventricular imaging was performed in the apical, parasternal long-axis, and parasternal short-axis views for assessments of systolic function, cavity diameter, diastolic function, and LV end-systolic and end-diastolic volumes. Twodimensional directed M-mode images of the short axis of the LV were taken inferior to the level of the papillary muscles for assessments of chamber diameter. All parameters were calculated in accordance with modified American Society of Echocardiography recommended guidelines.
Statistical Analysis
Data were analyzed using Graph-Pad Prism software, Version 5 (San Diego, CA). All results are expressed as the meanAEstandard error of the mean or median and interquartile range, as mentioned in the figure legends. Statistical comparisons between 2 groups were made using unpaired t tests or Mann-Whitney U test. For statistical comparisons of more than 2 groups, 1-way ANOVA followed by Bonferroni post hoc tests were used. We also used the Figure 1D , 1E, 1I, and 1J). As shown in Figure 1K , the gel-shift assay demonstrated (Figure 2A and 2B). Arteriolar density was analyzed 30 days after surgery in WT and Flk-1 +/À mice by a-smooth muscle actin staining (n=6/ group) ( Figure 2C and 2D). Arterioles were measured and divided into 3 categories based on their diameter: small (11-50 lm), medium (51-75 lm), and large vessels (≥76 lm) ( Figure S1 ). We observed a significant reduction in the density (numbers) of small vessels in the +/À mice subjected to MI; MI, myocardial infarction; p-, phosphorylated; PC, ischemic preconditioning; WT, wild type; the minus symbol (À) represents the negative control; WTMI, WT mice subjected to MI; WTS, WT mice subjected to sham surgery. Figure 2D ). We did not observe any difference in numbers related to large-sized arterioles in either Flk-1 +/À S or Flk-1 +/À MI mice 30 days after MI surgery.
The preoperative echocardiographic analysis performed to measure cardiac function showed no significant difference between WT and Flk-1 +/À mice (n=10/group) in either ejection fraction (EF; 65AE1.2% and 66AE1.8%) or fractional MI mice to observe changes in the distributions of collagen in the LV (Figure 2H and 2I) . The bar graphs in Figure 2I show the distribution of collagen in LV tissues of mice from the WTMI 
Peli1 is Negatively Regulated in Heterozygous Flk-1 Knockout Mice Following MI
To determine the impact of Flk-1-mediated Peli1 regulation, the LV risk areas were collected from WTMI and Flk-1 +/À mice (n=5-7/group) 8 hours and 4 days after the induction of MI and analyzed for Peli1 expression at the mRNA and protein levels using quantitative real-time PCR ( Figure 3A) and Western blot analysis, respectively ( Figure 3B and 3C Figure 3B and 3C) . At the baseline level also, we observed reduced expression of Peli1 in Flk-1 +/À mice (1.5-fold) compared with WT. We also examined Peli1 protein expression in 3 different conditions: in the normal heart, control heart subjected to sham surgery (CS), and after the MI procedure (CMI). A significant decrease in Peli1 expression after MI was observed in CMI hearts compared with CS or normal healthy hearts, revealing an important function for Peli1 in cardiovascular disease ( Figure 3D ). We did not observe any difference of Peli1 expression between CS and normal healthy heart.
Deletion of Peli1 Inhibits Proangiogenic Function in HUVECs: In Vitro Tube Formation, Proliferation, and Wound-Closure Assay
To explore the proangiogenic properties of Peli1, HUVECs were treated with C.siRNA or Peli1.siRNA for 48 hours.
Peli1.siRNA-treated HUVECs showed 90% knockdown of Peli1 expression after 48 hours compared with C.siRNA (Figure 3E) . The cells were treated with C.siRNA and Peli1.siRNA and were seeded over a Matrigel (Corning Incorporated, Corning, NY) layer with and without VEGF after 48 hours. Six hours after the cells were plated on the Matrigel, the function of HUVEC endothelial tube formation was quantified by counting the total number of endothelial branch points. The HUVECs treated with C.siRNA in the presence of VEGF (C.siRNA+VEGF) showed more endothelial branch points (19.64AE0.65) than the group treated with C.siRNA alone (10.33AE0.58). Peli1.siRNA abolished the VEGF-induced increase in tube formation, as represented by fewer branch points (2.56AE0.78). These data confirm that the complete knockdown of Peli1 in HUVECs has a detrimental effect on endothelial tube formation, even in the presence of VEGF ( Figure 3F and 3G) . Similar results were observed following an endothelial tube formation assay that replaced the VEGF stimulus with hypoxia/reoxygenation (H/R). Following exposure to H/R, HUVECs treated with C.siRNA showed a significant increase in endothelial branch points compared with those treated with C.siRNA alone (7.13AE0.57 versus 2.56AE0.29). The H/R-mediated increase in endothelial branch points was inhibited in the presence of Peli1.siRNA (0.53AE0.14) ( Figure 3H and 3I) . A fluorescence DNA quantification assay was performed using a CyQUANT kit to assess the effect of Peli1-mediated cell proliferation. The HUVECs treated with either C.siRNA or Peli1.siRNA for 48 hours were collected and uniformly reseeded onto a 96-well plate (5000 cells/well). The cells were subjected to H/R, followed by cell proliferation assays at 0, 24, and 48 hours. No significant difference in cell proliferation was observed between the treatment groups at 0 hours. However, the C.siRNA+H/R group showed significantly increased cell proliferation at both 24 hours (697.3AE11.27) and 48 hours (888.9AE25.86) compared with C.siRNA alone (251.1AE3.84 and 408AE11.12, respectively). This H/R-mediated increase in cell proliferation was inhibited in the Peli1.siRNA-treated group at both 24 hours (413.1AE21.69) and 48 hours (506.1AE29.71), indicating that Peli1 plays an important role in cell proliferation ( Figure 3J ).
An in vitro scratch assay was performed to assess the migration potential of HUVECs subjected to H/R. In the absence of Peli1 ( Figure 3K ), H/R-mediated wound closure was found to be significantly affected at 3, 6, 12, 24, and 36 hours after injury. Substantially more cell migration was observed in the C.siRNA+H/R group compared with the C.siRNA group at 3 hours (13.34AE1.01% versus 7.06AE1.6%), 6 MI group showed reduced levels of Peli1 compared with WTMI (n=3/group) (*P<0.05). D, Representative Western blot picture showing the expression of Peli1 in normal healthy and control hearts subjected to sham and after MI procedure (4 days after surgery) (n=3/group). E, Representative Western blot showing the expression of Peli1 in C.siRNA and Peli1.siRNA-treated HUVECs (n=3/group). F through L, Peli1 knockdown inhibits tube formation, cell proliferation, and migration. F and G, HUVECs were treated with either C.SiRNA or Peli1.siRNA, followed by VEGF treatment, and subjected to the tube-formation assay. G, Bar graph representing the total number of branch points in different treatment groups. The C.siRNA+VEGF treatment group showed an increased number of branch points compared with the C.siRNA-alone group, whereas the Peli1.siRNA+VEGF treatment group showed a decreased number of branch points compared with both the C.siRNA-alone and C.siRNA+VEGF treatment groups (n=3/group) (**P<0.01, ***P<0.001). H and I, HUVECs treated with either C.siRNA or Peli1.siRNA followed by H/R treatment and subjected to the tube-formation assay. I, Bar graph representing the total number of branch points in different treatment groups (n=3/group) (**P<0.01, ***P<0.001). The C.siRNA+H/R treatment group showed an increased number of branch points compared with C.siRNA, whereas the Peli1.siRNA+H/R treatment group showed a decreased number of branch points compared with C.siRNA+H/R. J, Bar graph representing the cell proliferation at 0, 24, and 48 hours after seeding (n=6/group). K, Representative pictures of wound closure in different treatment groups at 0 and 36 hours after treatment. L, Bar graph representing the percentage cell-wound closure at 3, 6, 12, 24, and 36 hours after injury in different treatment groups. The C.siRNA+H/R group showed increased cell proliferation and wound closure compared with the C.siRNA group, whereas the Peli1.siRNA+H/R group showed decreased cell proliferation and wound closure compared with the C.siRNA+H/R group. Values are meanAESEM. *P<0.05 compared with the C.siRNA group; # P<0.05 compared with the C.siRNA+H/R group. C.siRNA indicates control siRNA-treated group; CMI, control MI; CS, control sham; Flk-1 +/À MI, Flk-1 +/À mice subjected to MI; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H/R, hypoxia/ reoxygenation; HUVEC, human umbilical vein endothelial cells; MI, myocardial infarction; Peli1, Pellino-1; Peli1.siRNA, Peli1 siRNA treated group; VEGF, vascular endothelial growth factor; WT, wild-type; WTMI, WT mice subjected to MI.
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Thirunavukkarasu et al migration/wound closure was inhibited by Peli1.siRNA at 3 hours (6.14AE0.67%), 6 hours (9.73AE0.60%), 12 hours (15.72AE1.1%), 24 hours (14.74AE1.80%), and 36 hours (32.45AE1.66%) ( Figure 3L ).
Efficient In Vivo Peli1 Gene Expression in the Ischemic Myocardium of CD1 (WT) Mice Following Adenoviral Injection
Immunohistochemistry ( Figure S2 ) and Western blot analysis ( Figure 4A ) were performed 4 days after the administration of Ad-Peli1 to detect the expression of Peli1 in Ad-LacZ-and Ad-Peli1-injected hearts without MI (n=3/ group). Both of the techniques increased Peli1 expression in mice treated with Ad-Peli1, compared with the Ad-LacZtreated group. Additionally, Western blot analysis of hearts treated with Ad-LacZ or Ad-Peli1 and subjected to MI showed that Peli1 expression was more robust in the AdPeli1 group (9.9-fold) than in the Ad-LacZ group ( Figure 4B and 4C). 
Peli1 Promotes
Peli1 Promotes Cx43 Expression During MI
Immunofluorescent staining of gap junction protein (Cx43) was performed 4 days after MI. Expression of the Cx43 protein was higher in the Ad-Peli1MI group than in the Ad-LacZMI group. The expression intensity of Cx43 in the AdPeli1 group was similar to the expression pattern in the Ad-LacZS and Ad-Peli1S mice. The lower intensity of the fluorescent signal detected in the Ad-LacZMI group is indicative of the negative impact of MI ( Figure 5A ).
Peli1 Preserves the Infarcted Myocardium Through Increased Capillary and Arteriolar Densities
To assess the efficacy of Peli1 treatment in rescuing the infarcted myocardium, we analyzed the numbers of capillaries and arterioles in LV myocardial tissue samples by staining for CD31 + and a-smooth muscle actin-positive cells, respectively. Capillary counts in heart tissue samples Nuclei were stained with TO-PRO-3 Iodide (blue). Cx43 levels were similar between the Ad-LacZS and Ad-Peli1S groups. The Ad-LacZMI group showed reduced Cx43 levels compared with both the Ad-LacZS and Ad-Peli1S groups. However, the Ad-Peli1MI group showed increased Cx43 compared with the Ad-LacZMI group (n=5/group). B through F, Measurement of vessel density in mice treated with Ad-LacZ and Ad-Peil1 after the induction of MI in CD1 mice. B, Representative images of CD31 staining for capillary densities, 7 days after MI. Arrows indicate capillaries. C, Bar graph represents the quantitative analysis of capillary density in counts/mm 2 . The Ad-Peli1MI treatment group showed an increased capillary density compared with Ad-LacZMI (n=5/group). D through F, Bar graphs represent quantitative analysis of small, medium, and large-sized arteriole densities in counts/mm 2 (30 days after MI). The density of arterioles was increased in the Ad-Peli1MI group compared with Ad-LacZMI. Values are mean SEM, (n=6/group), *P<0.05 compared with the Ad-LacZMI group. Ad-LacZ indicates adenoviral vector encoding LacZ; Ad-LacZMI, CD1 mice subjected to MI followed by Ad-LacZ gene injection; Ad-LacZS, CD1 mice subjected to sham surgery followed by Ad-LacZ gene injection; Ad-Peli1, adenoviral vector encoding Peli1; Ad-Peli1MI, CD1 mice subjected to MI followed by Ad-Peli1 gene injection; Ad-Peli1S, CD1 mice subjected to sham surgery followed by Ad-Peli1 gene injection; Cx43, connexion 43; MI, myocardial infarction; S, Sham.
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Figure 5B and 5C. Staining for a-smooth muscle actin performed 30 days after the induction of MI was positive for arterioles in the ischemic myocardium of both the Ad-LacZ-and Ad-Peli1-treated groups. Representative pictures of small, medium, and large arterioles are shown in Figure S1 . Overall counts revealed a greater number of arterioles in the Ad-Peli1MI group compared with the Ad-LacZMI group. More specifically, medium-(5.2AE0.9 versus 1.4AE0.6 counts/mm 2 ) and largesized arterioles (3.5AE0.4 versus 0.7AE0.3 counts/mm 2 ) were significantly greater in number in the Ad-Peli1MI group compared with the Ad-LacZMI group. A similar trend was found for small-sized arterioles (33.4AE3 versus 25.2AE2.5 counts/mm 2 for the Ad-Peli1MI and Ad-LacZMI groups, respectively), but this difference did not reach statistical significance ( Figure 5D through 5F).
Peli1 Salvages the Infarcted Myocardium by Reducing Fibrosis and Preserving Cardiac Function
We evaluated the change in cardiac function attributed to Peli1 through echocardiography analysis. The overall status of heart function, as assessed through EF and FS, indicated the physiological status of the heart tissue. No significant difference in EF was observed between the Ad-LacZS and Ad-Peli1S groups, indicating a normal physiological heart status in these groups. However, mice in the Ad-LacZMI group demonstrated a significant reduction in EF compared with AdLacZS (32.96AE0.98% versus 69.14AE1.60%), indicating deterioration of cardiac function associated with MI. Similarly, animals in the Ad-Peli1MI group demonstrated a significant reduction in EF compared with the Ad-Peli1S group (48.49AE0.75% versus 66.82AE1.72%). However, EF was substantially increased in the Ad-Peli1MI group (48.49AE 0.75%) compared with Ad-LacZMI (32.96AE0.98%), which indicates an acquired cardioprotective effect associated with Peli1 treatment ( Figure 6A ). Similar findings were observed for FS; compared with the Ad-LacZMI group, Ad-Peli1MI mice showed improved cardiac function (16AE0.51% versus 24.54AE0.49%) ( Figure 6B ). An abnormal distribution of collagen in the myocardium is a hallmark feature of myocardial fibrosis. Qualitative analysis by PicroSirus Red staining showed extensive collagen deposition in the Ad-LacZMI group compared with Ad-Peli1MI mice ( Figure 6C ). Quantitative analysis similarly showed that the fibrotic area of mice in the Ad-Peli1MI group (16.67AE1.05%) was significantly reduced compared with that in the Ad-LacZMI group (29.42AE2.05%), as shown in Figure 6D .
Ad-Peli1 Gene Therapy Rescues the Ischemic Myocardium in Flk-1 +/À Mice
Rescue experiments were performed to determine whether Peli1 is involved in the loss of cardiac function in Flk-1 +/À mice subjected to MI and whether treatment with Peli1 using an adenoviral-mediated delivery system could recover heart function in vivo. These data indicate substantial treatment potential for Peli1-mediated promotion of cardiac repair in Flk-1 +/À mice following MI ( Figure 7M and 7N) . Taken together, these data convincingly demonstrate that Ad-Peli1 treatment preserves cardiac function in the myocardium of Flk-1 +/À mice by reducing ischemic loss of vessel density and myocardial fibrosis. The results indicate that gene therapy with Ad-Peli1 is strongly correlated with improved cardiac function, as assessed by echocardiogram and cardiac remodeling by myocardial fibrosis.
Discussion
In this study we have shown that Peli1 is a critical factor in VEGF signaling. The reduction of Peli1 expression in Flk-1 +/À mice at the baseline and after MI shows that Peli1 functions as a downstream molecule in VEGF/Flk-1 signaling and plays an important role in cardiac repair. In addition, we have also shown that the administration of Peli1 via an adenoviral LacZ; Ad-LacZMI, CD1 mice subjected to MI followed by Ad-LacZ gene injection; Ad-LacZS, CD1 mice subjected to sham surgery followed by Ad-LacZ gene injection; Ad-Peli1, adenoviral vector encoding Peli1; Ad-Peli1MI, CD1 mice subjected to MI followed by Ad-Peli1 gene injection; Ad-Peli1S, CD1 mice subjected to sham surgery followed by Ad-Peli1 gene injection; EF, ejection fraction; FS, fractional shortening; IQR, interquartile range; MI, myocardial infarction; S, Sham.
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vector induces an angiogenic response and improved heart function, and it ameliorates ventricular remodeling in a genetic knockout mouse model (Flk-1 +/À ).
Notably, we observed that inhibition of Flk-1 in a mouse model of MI caused reduced expression of several key signaling molecules and inhibition of Flk-1 phosphorylation, Figure 8B ). This is the first study to observe Peli1-mediated salvage of Flk-1 signaling in an MI model and to demonstrate its proangiogenic and cardioprotective properties.
Nuclear factor j light-chain enhancer of activated B cells controls the transcription of various angiogenic factors and is also involved in cytokine production and cell survival. Evidence indicates that oxidative stress and the production of free radicals secondary to MI lead to the activation of NFjB, which, in turn, induces the expression of genes involved in angiogenesis. 28, 29 In a mouse model the administration of pyrrolidine dithiocarbamate, an inhibitor of NFjB, has been shown to block neovascularization, indicating that activation of NFjB is an obligatory component of retinal angiogenesis. 30 Notably, Peli1 has been shown to upregulate levels of NFjB in inflammatory cells. Peli1 interacts with interleukin-1 receptor-associated kinase-4, interleukin-1 receptor-associated kinase, and tumor necrosis factor receptor-associated factor-6 to activate the IKK complex. The IKK complex, in turn, reacts with IjB and leads to the activation of NFjB. 31 In its dephosphorylated state IjB binds to NFjB in the cytoplasm, preventing it from entering the nucleus for transcription. However, when activated, the IKK complex triggers phosphorylation, ubiquitination, and ultimately the degradation of IjB, allowing for the activation of NFjB. 32 In this study we showed increased p-IjBa levels in the AdPeli1MI group compared with the Ad-LacZMI group. We observed reductions in p-IjBa and NFjB activity of mice with knockdown of Flk-1 in MI and ischemic preconditioning and in the inhibition of Flk-1 in vitro. We also observed increases in p-IjBa and NFjB in Peli1-treated mice. Upregulation of NFjB implicates Peli1 in the cardioprotective process, and the increase in p-IjBa offers insight into the mechanism through which Peli1 may work. The observed upregulation of p-MK2 in our study establishes that Peli1 can induce angiogenesis. Phosphorylation of MK2 significantly increases the activation of NFjB. 8 In microglial cells, MK2 activity is inhibited by tumor necrosis factor receptor-associated factor-3. Peli1 activates inhibitor of apoptosis-2, which in turn facilitates the degradation of tumor necrosis factor receptor-associated factor-3 and liberates MK2 to activate NFjB. 33 Accordingly, a deficiency of Peli1 in microglial cells has been shown to be associated with reduced activation of IAP2 and MK2. 14 In this study we established that Peli1 could also upregulate MK2 activation in heart tissue to stimulate angiogenesis. Upregulation of MK2 subsequently led to further expression of NFjB, providing support for the hypothesis that Peli1 increases activation of NFjB to promote cardiac repair. This finding not only provides evidence for the potential benefits of Peli1 but also offers further insight into its mechanism of action. Phosphatidylinositol 3-kinase (PI3K) and its downstream survival targets play important roles in signaling pathways involved in cardioprotection. 34 Some important downstream targets of PI3K include the phosphorylation of Akt and glycogen synthase kinase-3b. Increased levels of p-glycogen synthase kinase-3b stabilize and accumulate b-catenin in the cytosol, which is followed by translocation into the nucleus. 35 b-Catenin is known to be a strong mediator of angiogenesis. 36 Interestingly, in our study Peli1 gene therapy was found to trigger greater activation and nuclear translocation of bcatenin in the Ad-Peli1MI group than in the Ad-LacZMI group. Previously, we highlighted the importance of PC-mediated upregulation of b-catenin expression in angiogenic responses and cardioprotection 36 ; silencing of b-catenin was found to abolish PC-mediated increases in proangiogenic effects and heart health. 36 Therefore, activation of b-catenin by Peli1 could represent a promising strategy for improving cardiac function after MI. Increases in the expression of p-Akt and peNOS also strengthen the case for Peli1 as a proangiogenic molecule. In response to VEGF stimulation, Akt aids in endothelial cell migration and proliferation by inducing capillary formation, mobilizing endothelial cell progenitors, and increasing the production of eNOS. 37 In addition, Akt inhibits the production of caspase-9, a molecule that favors apoptosis. 38 Similarly, eNOS produces nitric oxide in endothelial cells, which increases vasodilation, vascular permeability, endothelial cell migration, and blood vessel maturation. A previous study showed that vildagliptin, a dipeptidyl Pellino-1 Gene Therapy Promotes Angiogenesis Thirunavukkarasu et al peptidase-4 inhibitor, stimulates ischemia-induced revascularization in WT mice but not in those that are deficient in eNOS. 39 In another study, the inhibition of eNOS or overexpression of dominant-negative Akt was observed to stunt VEGF-induced endothelial cell migration, whereas overexpression of active Akt promoted cell migration. 40 This study found significant increases in both Akt and eNOS activity in Ad-Peli1MI mice compared with Ad-LacZMI mice, indicating that Peli1 is involved in the induction of eNOS and that the potential mechanism by which it acts is through the activation of Akt. The increase in eNOS ultimately protects the heart from further damage.
Cx43 is a component of gap junctions that provides a means of cell-to-cell communication and aids in the electrical activation of heart tissue. A previous study found that VEGF upregulated expression of Cx43 and that inhibition of VEGF downregulated Cx43 expression. 41 Another study revealed that in cardiac organoids, or engineered simplified heart chambers, VEGF upregulated Cx43 and enhanced cardiac function. 42 A third study established that Cx43 overexpression in mesenchymal stem cells promoted angiogenesis in the infarcted myocardium, whereas knockdown of Cx43 by siRNA in MI reduced angiogenesis. 43 In this study we observed significant overexpression of Cx43 in Ad-Peli1MI mice compared with Ad-LacZMI mice. Because increased intracellular communication between cardiomyocytes allows for more synchronized and efficient cardiac healing, Peli1 therefore has the potential to improve networking between/among heart cells and allow for better recovery. We observed a significant increase in arteriogenesis 30 days following MI in Ad-Peli1 mice compared with Ad-LacZMI mice. Thirty days after the induction of MI, treatment with Ad-Peli1 clearly demonstrated increases in arterioles with diameters ranging from 51 to 75 lm (medium vessels) and >75 lm (large vessels). This finding is indicative of enhanced arteriogenesis in the treatment group and can likely be attributed to increased phosphorylation of MK2, Akt, eNOS, and IjBa and increased expression of b-catenin. These molecules contributed to +/À ) mice subjected to MI reduced Peli1 expression, followed by reduced phosphorylation of MK2, Akt, eNOS, and IjBa, reduced cell proliferation, migration, and vessel density, and to increased fibrosis. B, AdPeli gene therapy improves cardiac function and ameliorates ventricular remodeling after MI. Peli1 gene therapy triggered increased phosphorylation of Akt, eNOS, MK2, and IjBa, increased Cx43 expression, and reduced fibrosis. C, Ad-Peli1 gene therapy rescues Flk-1 KO mice after MI. Ad-Peli1 gene therapy leads to increased vessel density and cardiac function and to reduced fibrosis in Flk-1KO mice subjected to MI. KO indicates knockout; MI, myocardial infarction.
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Thirunavukkarasu et al neovascularization in the Peli1 treatment group, and the increase in vasculature would have subsequently allowed for increased oxygenation and nutrient supply to the damaged heart, hastening recovery. The cardioprotective properties of Peli1 and these molecules are also sufficient to explain the observed reduction in the extent of fibrosis in the Ad-Peli1MI group compared with the Ad-LacZMI group. Compared with both the WTMI and Ad-LacZMI groups, a significant increase in the cardiac function of Ad-Peli1MI mice was observed. This increase was correlated with enhanced EF, FS, systolic internal diameter, and diastolic internal diameter. MI has been attributed to decreased cardiac function as well as diastolic and systolic dysfunction, most likely because ischemic damage to the myocardium reduces its ability to contract. Increased cardiac function is also related to the observation of reduced fibrosis in Ad-Peli1 mice. The findings of this study can be attributed to increased vessel health and to the cardioprotective effect of Peli1 realized through its influence on the VEGF pathway. Overall, our results demonstrate that Flk-1 plays a significant role in the angiogenic process following ischemic damage. Inhibition of Flk-1 leads to the downregulation of various proangiogenic factors, including Peli1, reduced ability of the heart to undergo neovascularization, and increased damage to the myocardium (Figures 1, 2 , and 3A through 3C). Flk-1 provides the body with mechanisms to alleviate injury and protects the heart under ischemic threat. Accordingly, a reduction or inhibition of this critical molecule leads to a decline in the cardioprotective process. The protective effects of Peli1 on the heart under ischemic insult are shown in Figures 3 through 6 ; administration of Peli1 increases the expression of numerous proangiogenic factors, enhances neovascularization, and ameliorates many of the negative effects of MI. In addition, we have shown that Peli1 overexpression in Flk-1 +/À mice (Ad-Peli1 gene therapy) after MI rescues the ischemic myocardium ( Figure 8C ) from further injury, resulting in improved ventricular function through increased arteriogenesis and reduced cardiac fibrosis (Figure 7 ). In addition, we recently showed that Peli1 could increase the survivability of ischemic skin-flap tissue in Flk-1 +/À mice by increasing blood perfusion and reducing inflammation and necrosis. 11 The connection between the downregulation of Flk-1 and reduced expression of Peli1 suggests that the adverse consequences of reducing Flk-1 may be due to the reduction of Peli1.
In conclusion, we have successfully demonstrated that Peli1 plays a role in VEGF/Flk1 signaling in response to MI. Deletion of Flk1 abruptly suppressed VEGF-mediated signaling, resulting in the inhibition of angiogenesis and decreased heart function due to downregulation of Peli1 expression during MI. However, supplementation of Peli1 revived downstream VEGF signaling in Flk-1 knockout mice, induced angiogenesis, and increased cardiac repair and heart functions. These findings suggest that Peli1 is an important downstream target of VEGF. This innovative approach may prove to be a valuable therapeutic treatment for cardiovascular disease and may improve both the longevity and quality of life of affected patients. 
